Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lifecore Biomedical (LFCR)
NASDAQ:LFCR
Holding LFCR?
Track your performance easily
LFCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.68 - $8.90
Previous Close$7.28
Volume286.87K
Average Volume (3M)186.56K
Market Cap
$268.10M
Enterprise Value$433.94M
Total Cash (Recent Filing)$5.52M
Total Debt (Recent Filing)$127.92M
Price to Earnings (P/E)122.1
Beta0.75
Next Earnings
Jan 02, 2025EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding30,898,255
10 Day Avg. Volume279,969
30 Day Avg. Volume186,557
Standard Deviation0.20
R-Squared0.07
Alpha-0.00239
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-57.08
Price to Sales (P/S)1.75
Price to Cash Flow (P/CF)-87.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.38
Enterprise Value/Gross Profit10.37
Enterprise Value/Ebitda39.81
Forecast
1Y Price Target
$5.00Price Target Upside-32.61% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Lifecore Biomedical News
PremiumCompany Announcements
Lifecore Biomedical Strengthens Financial Position with Key Moves
PremiumCompany Announcements
Lifecore Biomedical Plans Strategic Growth and Transformation
Bulls Say, Bears Say
Bulls Say
Capacity ExpansionLifecore's new 5-head isolator filler has more than doubled its current capacity, potentially enabling it to generate approximately $300 million in revenue.
New Partnerships And AgreementsLifecore signed four new customers and numerous expansion agreements with existing customers, including a significant agreement with Lindy Biosciences.
Revenue Growth PotentialLifecore Biomedical aims to achieve 12% average annual revenue growth over the next three to four years and 25% or better EBITDA margins by the end of that mid-term window.
Bears Say
Financial PerformanceLifecore's balance sheet remains highly leveraged with perhaps $160 million in net debt and $43.4 million in convertible preferred stock, along with an expectation of negative free cash in FY/25.
Revenue DeclineThe company's CDMO revenue declined primarily due to a key customer's current inventory rebalancing activities.
ValuationThe stock's valuation is considered high at 22x EV/EBITDA, leading to a recommendation of maintaining a MARKET PERFORM investment rating.
---
Ownership Overview
29.44% Insiders
5.51% Mutual Funds
39.04% Other Institutional Investors
20.09% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LFCR FAQ
What was Lifecore Biomedical’s price range in the past 12 months?
Lifecore Biomedical lowest stock price was $3.68 and its highest was $8.90 in the past 12 months.
What is Lifecore Biomedical’s market cap?
Currently, no data Available
When is Lifecore Biomedical’s upcoming earnings report date?
Lifecore Biomedical’s upcoming earnings report date is Jan 02, 2025 which is in 2 days.
How were Lifecore Biomedical’s earnings last quarter?
Lifecore Biomedical released its earnings results on Oct 04, 2024. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.487 by -$0.043.
Is Lifecore Biomedical overvalued?
According to Wall Street analysts Lifecore Biomedical’s price is currently Overvalued.
Does Lifecore Biomedical pay dividends?
Lifecore Biomedical does not currently pay dividends.
What is Lifecore Biomedical’s EPS estimate?
Lifecore Biomedical’s EPS estimate is -$0.29.
How many shares outstanding does Lifecore Biomedical have?
Lifecore Biomedical has 36,827,030 shares outstanding.
What happened to Lifecore Biomedical’s price movement after its last earnings report?
Lifecore Biomedical reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.487. Following the earnings report the stock price went up 14.468%.
Which hedge fund is a major shareholder of Lifecore Biomedical?
Among the largest hedge funds holding Lifecore Biomedical’s share is Legion Partners Asset Management, Llc. It holds Lifecore Biomedical’s shares valued at 15M.
---
Lifecore Biomedical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (-32.61% Downside)
$5.00 (-32.61% Downside)
Blogger Sentiment
Bullish
LFCR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 19.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $6.5M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.10%
12-Months-Change
Fundamentals
Return on Equity
17.29%
Trailing 12-Months
Asset Growth
0.49%
Trailing 12-Months
Company Description
Lifecore Biomedical
Landec Corp. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Curation Foods, Lifecore, and Others. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Clara, CA.
---
LFCR Earnings Call
Q1 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of achievements and challenges. While Lifecore successfully streamlined operations, increased gross profit, and closed significant business deals, the company faced increased net losses, higher operating costs, and a decline in CDMO revenues. However, positive developments, such as the installation of a new isolator filler and successful capital raising, indicate potential for long-term growth.Read More>---
LFCR Stock 12 Month Forecast
Average Price Target
$5.00
▼(-32.61% Downside)
Technical Analysis
Best Analysts Covering LFCR
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+30.53%
assigned a buy rating 8 days ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +30.53% per trade.
---